Deutsche Bank Maintains a Hold Rating on GSK plc (GSK)

GSK plc (NYSE:GSK) is one of the best undervalued stocks to buy under $50. Deutsche Bank analyst Emmanuel Papadakis released a rating update for GSK plc (NYSE:GSK), maintaining a Hold rating on the stock with a £16 price target on November 4.

Is GSK plc (GSK) the Best Undervalued UK Stock to Buy Right Now?

GSK plc (NYSE:GSK) recently released its fiscal Q3 earnings on October 29, reporting that vaccines, specialty medicines, and general medicines drove sales, profit, and earnings growth. Total sales for the quarter were £8.5 billion, up 7% AER and 8% CER. Sales in Specialty Medicines rose 16% to £3.4 billion, those in Respiratory, Immunology & Inflammation rose 15% to £1.0 billion, while Oncology and HIV sales grew 39% and 12%, respectively. Vaccine sales in fiscal Q3 2025 rose 2% to £2.7 billion.

Management further reported that core operating profit rose 11% and core EPS experienced a 14% growth, reflecting the above mentioned growth in Specialty Medicines and Vaccines, higher royalty income, and disciplined increased investment in R&D portfolio progression in Oncology and Vaccines.

GlaxoSmithKline, GSK plc (NYSE:GSK) upgraded its 2025 guidance, and now expects core EPS growth of between 10% to 12% compared to the previous range of between 6% to 8%. It also expects core operating profit growth of between 9% to 11% compared to the previous 6% to 8%.

Formerly known as GlaxoSmithKline, GSK plc (NYSE:GSK) is a global healthcare and biopharmaceutical corporation that develops and distributes a range of vaccines, medications, and consumer health items. It is based in the United Kingdom and has over 20 vaccines in its portfolio, positioning it as a leader in vaccines, immunology, and respiratory therapies. The company also develops cancer treatments for multiple myeloma, ovarian cancer, and endometrial cancer, in addition to other drugs.

While we acknowledge the potential of GSK to grow, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than GSK and that has 100x upside potential, check out our report about this cheapest AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.